Abstract
Most of the signal transduction pathways are mediated by protein kinases regulating every aspect of cell function. Mutations which deregulate their expression or their function or both result in cancers. Therefore, protein kinase inhibitors have become the focus of development of new therapies for cancer. A comprehensive review of Choline kinase (ChoK) was published by us in 2003. Since then, molecular information of ChoK inhibitors has been accumulated. In this review, we intend to summarize the new lines of evidence that will include the design of the most active antiproliferative agents so far described against ChoK. Studies have been aimed at the establishment of structure-activity relationships and the structural parameters that define ChoK inhibitory and antiproliferative activities of a set of twenty-five acyclic biscationic pyridophane and forty acyclic biscationic quinolinephane compounds. The corresponding QSAR equation was obtained for the whole set of bisquinolinium compounds for the antiproliferative activity, taking into consideration the electronic parameter σR of R4, the molar refractivity (MR) of R8, and the lipophilic parameters clog P and πlinker. The most potent antiproliferative agent shows an IC50 = 0.45 μM, predicted by the QSAR equation, whilst its experimental value is IC50 = 0.20 μM. Finally, toxicity assays were performed for the most promising compounds because of their interesting antiproliferative activities [IC50 HT-29 = 0.70, 0.80, 1.50 and 1.90 μM] and low toxicity [LD50 = 16.7, 12.5, > 25 and > 20 μg/kg of mouse]. These biological activities justify further analysis for antitumoral assays under in vivo conditions.
Keywords: Ab initio calculations, Antitumor drugs, Bispyridinium compounds, Bicyclophanes, Bisquinolinium compounds, Cyclophanes, Choline Kinase, QSAR
Current Medicinal Chemistry
Title: (Q)SAR Studies to Design New Human Choline Kinase Inhibitors as Antiproliferative Drugs
Volume: 13 Issue: 11
Author(s): J. M. Campos, R. M. Sanchez-Martin, A. Conejo-Garcia, A. Entrena, M. A. Gallo and A. Espinosa
Affiliation:
Keywords: Ab initio calculations, Antitumor drugs, Bispyridinium compounds, Bicyclophanes, Bisquinolinium compounds, Cyclophanes, Choline Kinase, QSAR
Abstract: Most of the signal transduction pathways are mediated by protein kinases regulating every aspect of cell function. Mutations which deregulate their expression or their function or both result in cancers. Therefore, protein kinase inhibitors have become the focus of development of new therapies for cancer. A comprehensive review of Choline kinase (ChoK) was published by us in 2003. Since then, molecular information of ChoK inhibitors has been accumulated. In this review, we intend to summarize the new lines of evidence that will include the design of the most active antiproliferative agents so far described against ChoK. Studies have been aimed at the establishment of structure-activity relationships and the structural parameters that define ChoK inhibitory and antiproliferative activities of a set of twenty-five acyclic biscationic pyridophane and forty acyclic biscationic quinolinephane compounds. The corresponding QSAR equation was obtained for the whole set of bisquinolinium compounds for the antiproliferative activity, taking into consideration the electronic parameter σR of R4, the molar refractivity (MR) of R8, and the lipophilic parameters clog P and πlinker. The most potent antiproliferative agent shows an IC50 = 0.45 μM, predicted by the QSAR equation, whilst its experimental value is IC50 = 0.20 μM. Finally, toxicity assays were performed for the most promising compounds because of their interesting antiproliferative activities [IC50 HT-29 = 0.70, 0.80, 1.50 and 1.90 μM] and low toxicity [LD50 = 16.7, 12.5, > 25 and > 20 μg/kg of mouse]. These biological activities justify further analysis for antitumoral assays under in vivo conditions.
Export Options
About this article
Cite this article as:
Campos M. J., Sanchez-Martin M. R., Conejo-Garcia A., Entrena A., Gallo A. M. and Espinosa A., (Q)SAR Studies to Design New Human Choline Kinase Inhibitors as Antiproliferative Drugs, Current Medicinal Chemistry 2006; 13 (11) . https://dx.doi.org/10.2174/092986706776872961
DOI https://dx.doi.org/10.2174/092986706776872961 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tumor Necrosis Factor: Renaissance as a Cancer Therapeutic?
Current Cancer Drug Targets Artificial Intelligence Techniques for Colorectal Cancer Drug Metabolism: Ontologies and Complex Networks
Current Drug Metabolism Selection of Active Antiviral Compounds Against COVID-19 Disease Targeting Coronavirus Endoribonuclease Nendou/NSP15 Via Ligandbased Virtual Screening and Molecular Docking
Letters in Drug Design & Discovery Peptide Drugs QSAR Modeling Based on a New Descriptor of Amino Acids- SVGT
Letters in Drug Design & Discovery Computational Approaches in the Discovery and Development of Therapeutic and Prophylactic Agents for Viral Diseases
Current Topics in Medicinal Chemistry Natural Products as Potential Agents against SARS-CoV and SARSCoV- 2
Current Medicinal Chemistry Subject Index to Volume 5
Current Protein & Peptide Science The Effect of Relaxation Technique (Jacobsen and Benson) on Depression, Anxiety, and Stress in Patients with Multiple Sclerosis
Current Psychiatry Research and Reviews Treating Sarcopenia in Older and Oldest Old
Current Pharmaceutical Design Soluble Epoxide Hydrolase: A Novel Target for the Treatment of Hypertension
Recent Patents on Cardiovascular Drug Discovery Recursive Partitioning Analysis and Anti-Tubercular Screening of 3- Aminopyrazine-2-Carbohydrazide Derivatives
Letters in Drug Design & Discovery Optic Nerve and Cerebral Edema in the Course of Diabetic Ketoacidosis
Current Neuropharmacology Inhibition of Quorum Sensing in Staphylococcus spp.
Current Pharmaceutical Design Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design Synthesis and Antibacterial Properties of Oxazolidinones and Oxazinanones
Anti-Infective Agents in Medicinal Chemistry Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues
Current Medicinal Chemistry Human Multidrug Transporter ABCG2, a Target for Sensitizing Drug Resistance in Cancer Chemotherapy
Current Medicinal Chemistry Overview of COVID-19 Pandemic: Its Management and Prevention in Light of the Indian Traditional Medicine System
Current Traditional Medicine Hepatic Involvement as Hyperbilirubinemia in Patients with COVID-19: Case Series from Iran
Infectious Disorders - Drug Targets Recent Progress on Anti-Liver Fibrosis Candidates in Patents of Herbal Medicinal Products
Recent Patents on Food, Nutrition & Agriculture